Report Scope: The scope of this report is broad and covers product type, end users, techniques and applications of cancer cell analysis instruments and consumables. Revenue forecasts from 2018 through 2023 are given for each of the segments and regional markets with estimated values derived from the manufacturers’ total revenues.
The report also includes a discussion of the major players across each region and explains the major drivers and regional dynamics of the global cancer cell analysis market and current trends within the industry.
The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors.
Report Includes: - 100 data tables and 91 additional tables - Detailed overview of the global market for cancer cell analysis in instruments, reagents and consumables - Analyses of the global market trends with data from 2017 to 2018, and projections of compound annual growth rates (CAGRs) through 2023 - Qualitative and quantitative study of the cancer cell analysis industry by product type, end user, analyses technique, application - Assessment of the major drivers and regional dynamics of the global cancer cell analysis market and current trends within the industry - Emphasis on the vendor landscape and detailed profiles of the major vendors in the cancer cell analysis market, including Abbott Laboratories, Bio-Rad Laboratories Inc., GE Healthcare, Merck Millipore, QIAGEN Inc., Siemens Healthcare and ThermoFischer Scientific
Summary Cancer cell analysis is the investigation of basic cancerous cell biology, its relation to disease, and the development of novel small molecule, cell-based therapies and biotherapeutics for cancer.It also helps explain the complex defects in communication between the cells that alter normal programs of transcription, proliferation, cell viability and proliferation, RNA expression, cancer immunotherapy, drug discovery and development, and flow cytometry, among others.
Cancer cell analysis has proven to be extremely beneficial across therapeutic and diagnostic applications. Furthermore, the global market for cancer cell analysis will witness rapid growth over the forecast period from 2018 through 2023 as the forecast for cancer prevalence is high.
Furthermore, increasing incidences of different types of cancers across the globe, and rising investments for cancer-based research coupled with increasing importance of cell assay-based drug development are the major factors triggering the growth of the global cancer cell analysis market. In addition, factors such as increasing demand for the development of personalized medicine for cancer and advancements in stem cell analysis and biomarker technology are also providing traction during the forecast period.
According to OurWorld in Data, approximately 19 million people had cancer in 1990.That number increased more than twofold by 2016, as the figure hiked up to 42 million worldwide.
Breast cancer has been identified as the leading type of cancer with 8.0 people diagnosed in 2016. This compares to 6.3 million diagnosed with colon and rectum cancer, 5.7 million with prostate and tracheal cancer and 2.8 million with bronchus and lung cancer in the same year. Hence, the increasing incidences of various cancer forms calls for cancer cell analysis in diagnostic and therapeutic areas. Moreover, rising investments for cancer-based research is also a major parameter fuelling the global market for cancer cell analysis growth. According to theWorldwide Cancer Research Fund, throughout the globe cancer research funding is increasing by 10% annually. By 2020, total expenditures on cancer research are anticipated to reach $177 billion. In addition, Cancer Research U.K., the U.S. federal government, and the Australian government, among others, are investing heavily in cancer research.
The global market for cancer cell analysis is projected to rise at a CAGR of REDACTED during the forecast period of 2018 through 2023. In 2023, total revenues are expected to reach more than REDACTED, registering an increment of REDACTED over the REDACTED seen in 2017.
The report provides an analysis based on each market segment, which includes product type, end users, techniques and applications.The product type segment is further subsegmented into consumables and instruments.
The cancer cell analysis market by consumables held the largest market share of REDACTED in 2017 in terms of revenue followed by instruments.In 2023, total revenue from consumables is expected to reach more than REDACTED.
However, the instruments segment is estimated to rise at the highest CAGR of REDACTED through 2023.
Our reports have been used by over 10K customers, including:
Global Cell Isolation Market By Product (Consumables and Instruments), By Cell Type (Human Cells and Animal Cells), By Source (Bone Marrow, Cord Blood/Embryonic Stem Cells, Adipose Tissue), By Technique (Centrifugation-Based Cell Isolation, Surface Marker-Based Cell Isolation, Filtration-Based Cell Isolation), By Application (Biomolecule...
306 pages •
By Global Industry Analysts
• May 2021
Global Cell Harvesting Market to Reach $359.2 Million by 2026
Cell harvesting is a next-generation technique that involves collection of stem cells from the culture media for R&D and therapeutic applications. Growth in the global market is spurred by of increasing investments...
The global single-use assemblies market is projected to reach USD 6.3 billion by 2026 from USD 2.2 billion in 2021, at a CAGR of 23.3% during the forecast period. The growth of the single-use assemblies market can primarily be attributed to the major advantages of single-use technologies as compared to traditional stainless-steel assemblies,...
“Axial spondyloarthritis - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Axial spondyloarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route...
The microcarrier market is majorly driven by factors such as rising demand for cell-based vaccines and therapeutics, the rapid growth of biologics and biosimilar industry, and increasing R&D and availability of funding for cell therapy research. Many of the current biologics in the pipeline are targeting the indications, which are small-molecule...
The Global Biologics CDMO Market was valued at USD 9.93 billion in 2020 and is expected to reach USD 18.63 billion by 2026, registering a CAGR of 10.87% during the forecast period (2021-2026). The CMO/CDMO service sector is uniquely positioned to address some of the challenges that drug developers are facing amid the COVID-19 pandemic....
Erythropoietin Drugs Market by Product Type (Epoetin-Alfa, Epoetin-Beta, and Darbepoetin-Alfa, Others) and Application (Hematology, Kidney Disorder, Cancer, Others): Global Opportunity Analysis and Industry Forecast, 2021–2028 The erythropoietin drugs market was valued at $9,243.12 million in 2020, and is projected...
REPORT OBJECTIVES The report “ Lactase Enzymes Market: Global Market Intelligence (2020-2030) provides market intelligence on the different market segments, based on Market Dynamics, Distribution Channel, Product type, and geography. Market size and forecast (2020-2030) has been provided in the report. The primary objectives...
Apoptosis Regulator BAX - Drugs In Development, 2021 Summary Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Apoptosis regulator BAX or bcl-2-like protein 4 is a protein is encoded by the BAX gene. It accelerates programmed cell death by antagonizing the apoptosis repressor BCL2....
Cause-Specific Mortality Rate
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.